Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
about
Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damagePhase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.Oncolytic adenovirus-expressed RNA interference of O(6)-methylguanine DNA methyltransferase activity may enhance the antitumor effects of temozolomide.Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicityAcquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chainAdenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesThe ups and downs of DNA repair biomarkers for PARP inhibitor therapiesPediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target.O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomasTemozolomide induces senescence but not apoptosis in human melanoma cells.Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerPoly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activityPhase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedulesNF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.A conditionally replicating adenovirus expressing IL-24 acts synergistically with temozolomide to enhance apoptosis in melanoma cells in vitro.Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines.An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cellsDacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.PARP inhibitors and cancer therapy - early results and potential applications.Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
P2860
Q28487714-048C4A5E-9BB8-461D-A8EF-F992417FAC84Q33404493-4CAEAE17-71B5-4C7C-9548-9D84E951CB66Q33729396-7B62DE29-75DE-43B3-943B-6853466D036CQ34293315-9885BFAF-CC03-4589-A1CC-C220C68B3C44Q34339861-95DEB7BB-3374-404F-8549-36421A0457E5Q34400848-801DEE90-9FC5-4F03-B215-2FC081C42298Q34488011-5C87077C-9286-4774-ACA5-A5A345CD3219Q35212640-0BF05397-6F83-4372-8C74-ED75697E37D3Q35232277-60502EB3-EA0D-405C-AF10-0252FDBB3D2BQ35568495-FF56DDAD-8DAE-4263-8204-2DB2B1250F27Q36288503-232F1CB5-59C1-4DB9-A01D-89B27FCEC6C9Q36611497-297CEE83-4DEF-4FF3-B42B-FF1278070B80Q36941966-52B19975-626F-47BD-B5C8-339AD975240AQ37089235-86A00321-FE1B-48E4-805A-A734BF9CE81FQ37121130-D2747B78-B321-46D1-A12F-16098366E196Q37216709-1A55F617-4B9B-4482-8E0A-AE224A7810ACQ37711694-66A44167-02A0-42D6-BE62-B23493D8168EQ38677373-69EF5E68-D647-4FA8-B5FD-AD472C422960Q38733784-FF6C2378-41E6-41E7-B9AE-90ED20B4F6B3Q38742492-68672337-45E7-486D-9114-D8872081B3C6Q39007680-474FE6F8-BE4E-4E8D-908E-483621F611CBQ39486283-D8245EAA-80B6-4269-A26E-A415BBF3FE0DQ39830817-15796D3D-F736-4A6F-8EAD-73D52EF5E33EQ41315657-443A0AB3-AE2B-4D56-A7EB-4AC02E4963FEQ41696382-F0EB9336-6947-4FAB-8DA5-C96A7AC224A1Q45197517-456E242D-56CC-4ABC-AE95-F75AA3E335F2Q46013098-8798C987-7010-4C4A-9D8B-BC4DFD0B33B2Q46344539-99126D4A-AB74-40FE-96D9-166711145F89Q47710977-F6E63064-1914-42BF-99DF-18B340674D7BQ50980480-802AFA98-9D1E-45F9-B35C-1F678DAD0C58Q51487611-D9BF6A00-1983-4D07-8EBF-811701DD4A09Q57569610-ADACEE63-5877-48EA-962D-306433507BDC
P2860
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Temozolomide pharmacodynamics ...... poly(ADP-ribose) polymerase-1.
@ast
Temozolomide pharmacodynamics ...... poly(ADP-ribose) polymerase-1.
@en
type
label
Temozolomide pharmacodynamics ...... poly(ADP-ribose) polymerase-1.
@ast
Temozolomide pharmacodynamics ...... poly(ADP-ribose) polymerase-1.
@en
prefLabel
Temozolomide pharmacodynamics ...... poly(ADP-ribose) polymerase-1.
@ast
Temozolomide pharmacodynamics ...... poly(ADP-ribose) polymerase-1.
@en
P2093
P50
P1476
Temozolomide pharmacodynamics ...... poly(ADP-ribose) polymerase-1
@en
P2093
A Hilary Calvert
Amanda J Watson
Anna Olsen
Christopher Jones
David R Newell
E Ruth Plummer
Gail McGown
Geoffrey P Margison
Ian Hickson
Mark R Middleton
P304
P356
10.1158/1078-0432.CCR-04-2353
P407
P577
2005-05-01T00:00:00Z